

N Paul Ogori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3966074/publications.pdf>

Version: 2024-02-01

55
papers

3,179
citations

304368

22
h-index

182168

51
g-index

55
all docs

55
docs citations

55
times ranked

2654
citing authors

#	ARTICLE	IF	CITATIONS
1	A decade into thyroid molecular testing: where do we stand?. Journal of the American Society of Cytopathology, 2022, 11, 59-61.	0.2	5
2	Accuracy of definitive rapid onsite evaluation cytopathology diagnoses: Assessment of potentially critical diagnoses as a quality assurance measure. Journal of the American Society of Cytopathology, 2022, 11, 133-141.	0.2	2
3	Thyroid cytology smear slides: An untapped resource for ThyroSeq testing. Cancer Cytopathology, 2021, 129, 33-42.	1.4	30
4	Impact of molecular testing on detecting mimics of oncocytic neoplasms in thyroid fine-needle aspirates diagnosed as follicular neoplasm of Hurthle cell (oncocytic) type. Cancer Cytopathology, 2021, 129, 788-797.	1.4	9
5	Molecular alterations in Hurthle cell nodules and preoperative cancer risk. Endocrine-Related Cancer, 2021, 28, 301-309.	1.6	23
6	Comparison of quantitative internal and external measures of performance for trainees in cytopathology fellowships. Journal of the American Society of Cytopathology, 2021, 10, 495-503.	0.2	2
7	Molecular testing and thyroid nodule management in North America. Gland Surgery, 2020, 9, 1628-1638.	0.5	10
8	The Clinical Utility of Molecular Testing in the Management of Thyroid Follicular Neoplasms (Bethesda IV Nodules). Annals of Surgery, 2020, 272, 621-627.	2.1	23
9	Molecular-derived estimation of risk of malignancy for indeterminate thyroid cytology diagnoses. Journal of the American Society of Cytopathology, 2020, 9, 213-220.	0.2	23
10	Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict Patient Outcome. Clinical Gastroenterology and Hepatology, 2020, , .	2.4	5
11	Comparison of urinary cytology and fluorescence in situ hybridization in the detection of urothelial neoplasia: An analysis of discordant results. Diagnostic Cytopathology, 2019, 47, 282-288.	0.5	8
12	GLIS rearrangements in thyroid nodules: A key to preoperative diagnosis of hyalinizing trabecular tumor. Cancer Cytopathology, 2019, 127, 560-566.	1.4	21
13	Percutaneous computed tomography-guided biopsy performed by thoracic surgeons in 955 patients: A paradigm shift in image-guided thoracic procedures. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 1239-1245.	0.4	5
14	Thyroid Fine-Needle Aspiration Cytology Molecular Testing in the USA. , 2019, , 451-463.		0
15	Comparison of the collection approaches of 2 large thyroid fine-needle aspiration practices reveals differing advantages for cytology and molecular testing adequacy rates. Journal of the American Society of Cytopathology, 2019, 8, 243-249.	0.2	4
16	Benign call rate and molecular test result distribution of ThyroSeq v3. Cancer Cytopathology, 2019, 127, 161-168.	1.4	50
17	Incidental Diagnosis of Parathyroid Lesions by Preoperative Use of Next-Generation Molecular Testing. World Journal of Surgery, 2018, 42, 2840-2845.	0.8	2
18	Cancer risk and clinicopathological characteristics of thyroid nodules harboring thyroid-stimulating hormone receptor gene mutations. Diagnostic Cytopathology, 2018, 46, 369-377.	0.5	30

#	ARTICLE	IF	CITATIONS
19	Correct extent of thyroidectomy is poorly predicted preoperatively by the guidelines of the American Thyroid Association for low and intermediate risk thyroid cancers. <i>Surgery</i> , 2018, 163, 81-87.	1.0	46
20	Young Investigator Challenge: Molecular testing in noninvasive follicular thyroid neoplasm with papillary-like nuclear features. <i>Cancer Cytopathology</i> , 2017, 125, 292-293.	1.4	2
21	Critical diagnoses in cytopathology: Experience at a large medical center. <i>Cancer Cytopathology</i> , 2017, 125, 726-730.	1.4	4
22	The influence of the noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) resection diagnosis on the false-positive thyroid cytology rate relates to quality assurance thresholds and the application of NIFTP criteria. <i>Cancer Cytopathology</i> , 2017, 125, 692-700.	1.4	39
23	Preoperative detection of RAS mutation may guide extent of thyroidectomy. <i>Surgery</i> , 2017, 161, 168-175.	1.0	56
24	A diagnostically difficult case of a cellular pleural fluid: Morphology, immunohistochemistry, and fluorescence in situ hybridization study. <i>CytoJournal</i> , 2017, 14, 18.	0.8	0
25	Endoscopic ultrasound-guided FNA and P core biopsy in sampling pancreatic and intra-abdominal masses. <i>Cancer Cytopathology</i> , 2016, 124, 110-121.	1.4	29
26	Epithelioid Hemangioendothelioma: a Rare Primary Thyroid Tumor with Confirmation of WWTR1 and CAMTA1 Rearrangements. <i>Endocrine Pathology</i> , 2016, 27, 147-152.	5.2	8
27	Committee I: Indications for pulmonary cytology sampling methods. <i>Diagnostic Cytopathology</i> , 2016, 44, 1010-1023.	0.5	9
28	Significance of what is not sampled: Characteristics of thyroid nonmicrocarcinomas (>1.0 cm) that were not targeted. <i>Cancer Cytopathology</i> , 2015, 123, 678-683.	1.4	1
29	Tumor Genotype Determines Phenotype and Disease-related Outcomes in Thyroid Cancer. <i>Annals of Surgery</i> , 2015, 262, 519-525.	2.1	100
30	Adequacy of Core Needle Biopsy Specimens and Fine-Needle Aspirates for Molecular Testing of Lung Adenocarcinomas. <i>American Journal of Clinical Pathology</i> , 2015, 143, 193-200.	0.4	79
31	Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology. <i>Thyroid</i> , 2015, 25, 1217-1223.	2.4	344
32	Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. <i>Cancer</i> , 2014, 120, 3627-3634.	2.0	445
33	Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. <i>Cancer Cytopathology</i> , 2014, 122, 873-882.	1.4	63
34	PAX8/PPAR γ 3 Rearrangement in Thyroid Nodules Predicts Follicular-Pattern Carcinomas, in Particular the Encapsulated Follicular Variant of Papillary Carcinoma. <i>Thyroid</i> , 2014, 24, 1369-1374.	2.4	83
35	Ancillary Studies in Thyroid Cytopathology. <i>Surgical Pathology Clinics</i> , 2014, 7, 47-60.	0.7	1
36	Correlation of Ultrasound Findings With the Bethesda Cytopathology Classification for Thyroid Nodule Fine-Needle Aspiration: A Primer for Radiologists. <i>American Journal of Roentgenology</i> , 2013, 201, W487-W494.	1.0	14

#	ARTICLE	IF	CITATIONS
37	Nodule size is an independent predictor of malignancy in mutation-negative nodules with follicular lesion of undetermined significance cytology. <i>Surgery</i> , 2013, 154, 730-738.	1.0	34
38	<i>RAS</i> Mutations in Thyroid FNA Specimens Are Highly Predictive of Predominantly Low-Risk Follicular-Pattern Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E914-E922.	1.8	128
39	<i>BRAF</i> mutation detection in indeterminate thyroid cytology specimens. <i>Cancer Cytopathology</i> , 2013, 121, 197-205.	1.4	71
40	Colloid-rich follicular neoplasm/suspicious for follicular neoplasm thyroid fine-needle aspiration specimens: Cytologic, histologic, and molecular basis for considering an alternate view. <i>Cancer Cytopathology</i> , 2013, 121, 718-728.	1.4	20
41	Intraoperative Pathologic Examination in the Era of Molecular Testing for Differentiated Thyroid Cancer. <i>Journal of the American College of Surgeons</i> , 2012, 215, 546-554.	0.2	18
42	Bronchoscopic and transthoracic cytology and biopsy for pulmonary nonsmall cell carcinomas: Performance characteristics by procedure and tumor type. <i>Diagnostic Cytopathology</i> , 2012, 40, 659-663.	0.5	10
43	Thyroid Cytology: Challenges in the Pursuit of Low-Grade Malignancies. <i>Radiologic Clinics of North America</i> , 2011, 49, 435-451.	0.9	3
44	Variability in the Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Diagnosis in the Bethesda System for Reporting Thyroid Cytopathology: Sources and Recommendations. <i>Acta Cytologica</i> , 2011, 55, 492-498.	0.7	136
45	Selective screening for nongynecologic cytology specimens: Modifying the screening process for improved efficiency and practice. <i>Diagnostic Cytopathology</i> , 2011, 39, 717-722.	0.5	1
46	Impact of Mutational Testing on the Diagnosis and Management of Patients with Cytologically Indeterminate Thyroid Nodules: A Prospective Analysis of 1056 FNA Samples. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3390-3397.	1.8	712
47	Contribution of molecular testing to thyroid fine-needle aspiration cytology of follicular lesion of undetermined significance/atypia of undetermined significance. <i>Cancer Cytopathology</i> , 2010, 118, 17-23.	1.4	229
48	A Novel Complex BRAF Mutation Detected in a Solid Variant of Papillary Thyroid Carcinoma. <i>Endocrine Pathology</i> , 2009, 20, 122-126.	5.2	74
49	Discrepancy analysis, communication, and feedback for cytotechnologist quality improvement of nongynecologic cytopathology. <i>Diagnostic Cytopathology</i> , 2006, 34, 265-269.	0.5	5
50	Double Slide Viewing as a Cytology Quality Improvement Initiative. <i>American Journal of Clinical Pathology</i> , 2006, 125, 526-533.	0.4	19
51	Cytologic-histologic correlation of nongynecologic cytopathology cases: Separation of determinate from indeterminate cytologic diagnoses for analysis and monitoring of laboratory performance. <i>Diagnostic Cytopathology</i> , 2003, 28, 28-34.	0.5	9
52	Dramatic response of adult Wilms tumor to paclitaxel and cisplatin. , 2000, 34, 296-298.		11
53	Cytopathology of high-grade papillary thyroid carcinomas: Tall-cell variant, diffuse sclerosing variant, and poorly differentiated papillary carcinoma. , 1999, 20, 19-23.		29
54	Cytopathology of high-grade papillary thyroid carcinomas: Tall-cell variant, diffuse sclerosing variant, and poorly differentiated papillary carcinoma. <i>Diagnostic Cytopathology</i> , 1999, 20, 19-23.	0.5	1

#	ARTICLE	IF	CITATIONS
55	Occurrence of Human Papillomavirus DNA in Primary Lung Neoplasms. Cancer, 1992, 69, 693-697.	2.0	94